ICER experts tussle over Aduhelm unanimously slap down new Alzheimer’s drug
Is there enough evidence to show Biogen’s new Alzheimer’s drug Aduhelm provides a benefit to patients, physicians and society beyond the current standard care? The answer from a group of ICER experts, perhaps unsurprisingly, was “no.” During a daylong meeting Thursday that featured debate over the drug’s cost and more, experts voted 15 to 0 that